Literature DB >> 25755989

Anti-angiogenic poly-L-lysine dendrimer binds heparin and neutralizes its activity.

Khuloud T Al-Jamal1, Wafa T Al-Jamal2, Kostas Kostarelos2, John A Turton3, Alexander T Florence2.   

Abstract

The interaction between heparin, a polyanion, and a polycationic dendrimer with a glycine core and lysine branches Gly-Lys63(NH2)64 has been investigated. Complexation was assessed by transmission electron microscopy, size and zeta potential measurements, methylene blue spectroscopy, and measuring the anti-coagulant activity of heparin in vitro and in vivo. Complete association between the heparin and the dendrimer occurred a 1:1 mass ratio (2:1 molar ratio or +/-charge ratio) with formation of quasi-spherical complexes in the size range of 99-147 nm with a negative zeta potential (-47 mV). Heparin-dendrimer (dendriplex) formation led to a concentration-dependent neutralization of the anticoagulant activity of heparin in human plasma in vitro, with complete loss of activity at a 1:1 mass ratio. The anticoagulant activity of the dendriplexes in Sprague-Dawley rats was also evaluated after subcutaneous administration with uncomplexed heparin as a comparator. The in vivo anticoagulant activity of heparin in plasma, evaluated using an antifactor Xa assay, was abolished after complexation. Measurement of [(3)H]-heparin showed that both free heparin and dendriplexes were present in plasma and in organs. Such data confirmed stably the formation of dendriplexes, which could be essential in developing novel dendrimer-based anti-angiogenic therapeutics suitable in combinatory therapeutics and theranostics.

Entities:  

Keywords:  Angiogenesis; Anticoagulant; Complexation; Dendriplexes

Year:  2011        PMID: 25755989      PMCID: PMC4166578          DOI: 10.1016/j.rinphs.2011.12.002

Source DB:  PubMed          Journal:  Results Pharma Sci        ISSN: 2211-2863


  11 in total

1.  A good practice guide to the administration of substances and removal of blood, including routes and volumes.

Authors:  K H Diehl; R Hull; D Morton; R Pfister; Y Rabemampianina; D Smith; J M Vidal; C van de Vorstenbosch
Journal:  J Appl Toxicol       Date:  2001 Jan-Feb       Impact factor: 3.446

2.  Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains.

Authors:  Weiqing Zhang; Richard Swanson; Yan Xiong; Benjamin Richard; Steven T Olson
Journal:  J Biol Chem       Date:  2006-10-13       Impact factor: 5.157

3.  Heparin-polypeptide interactions in aqueous solution.

Authors:  R A Gelman; J Blackwell
Journal:  Arch Biochem Biophys       Date:  1973-11       Impact factor: 4.013

4.  Protamine is an inhibitor of angiogenesis.

Authors:  S Taylor; J Folkman
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

5.  Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.

Authors:  Khuloud T Al-Jamal; Wafa' T Al-Jamal; Simon Akerman; Jennifer E Podesta; Açelya Yilmazer; John A Turton; Alberto Bianco; Neil Vargesson; Chryso Kanthou; Alexander T Florence; Gillian M Tozer; Kostas Kostarelos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-11       Impact factor: 11.205

6.  Heparin binding peptides co-purify with glycosaminoglycans from human plasma.

Authors:  M Chevanne; R Caldini; G Manao; M Ruggiero; S Vannucchi
Journal:  FEBS Lett       Date:  1999-12-10       Impact factor: 4.124

7.  Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP.

Authors:  A Leone-Bay; D R Paton; B Variano; H Leipold; T Rivera; J Miura-Fraboni; R A Baughman; N Santiago
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

8.  Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.

Authors:  T D Bjornsson; D E Schneider; A R Hecht
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

9.  An intrinsically fluorescent dendrimer as a nanoprobe of cell transport.

Authors:  Khuloud T Al-Jamal; Pakatip Ruenraroengsak; Nicholas Hartell; Alexander T Florence
Journal:  J Drug Target       Date:  2006-07       Impact factor: 5.121

10.  Mast cell heparin stimulates migration of capillary endothelial cells in vitro.

Authors:  R G Azizkhan; J C Azizkhan; B R Zetter; J Folkman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

Review 2.  Dendrimer-based drug delivery systems: history, challenges, and latest developments.

Authors:  Juan Wang; Boxuan Li; Li Qiu; Xin Qiao; Hu Yang
Journal:  J Biol Eng       Date:  2022-07-25       Impact factor: 6.248

3.  In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.

Authors:  Tong Li; Zhiyun Meng; Xiaoxia Zhu; Hui Gan; Ruolan Gu; Zhuona Wu; Taoyun Liu; Peng Han; Jiarui Gao; Su Han; Guifang Dou
Journal:  FEBS Open Bio       Date:  2021-08-12       Impact factor: 2.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.